Augmenting Venetoclax Activity Through Signal Transduction in AML

Venetoclax, a small-molecule B-cell lymphoma 2 (BCL-2) inhibitor, selectively eradicates leukemic stem cells (LSCs). While venetoclax has revolutionized the treatment of acute myeloid leukemia (AML), treatment failure and disease relapse are common. Mechanisms underlying venetoclax resistance are su...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouligny, Ian Michael, Maher, Keri Renee, Grant, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997087/
https://www.ncbi.nlm.nih.gov/pubmed/36911757
http://dx.doi.org/10.33696/signaling.4.085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997087/
https://www.ncbi.nlm.nih.gov/pubmed/36911757
http://dx.doi.org/10.33696/signaling.4.085

Ejemplares similares